Breaking News Instant updates and real-time market news.

GILD

Gilead

$68.17

-2.01 (-2.86%)

, RHHBY

Roche

$0.00

(0.00%)

20:38
12/09/18
12/09
20:38
12/09/18
20:38

Gilead to hire Roche's Daniel O'Day as next CEO, WSJ reports

Gilead Sciences (GILD) plans to hire Daniel O'Day as its next CEO as it looks to revive sales and recover from a disappointing deal, Jonathan Rockoff and Joseph Walker of Wall Street Journal report, citing people familiar with the matter. Day comes from Roche (RHHBY) where he most recently ran the company's pharmaceuticals group, sources tell the Journal. An announcement could come as soon as Monday, Rockoff and Walker say. Reference Link

GILD

Gilead

$68.17

-2.01 (-2.86%)

RHHBY

Roche

$0.00

(0.00%)

  • 11

    Dec

  • 24

    Dec

  • 18

    Mar

GILD Gilead
$68.17

-2.01 (-2.86%)

10/31/18
EVER
10/31/18
NO CHANGE
EVER
Outperform
Gilead sales not at risk from UnitedHealth promotions, says Evercore ISI
Evercore ISI analyst Umer Raffat attributes the pullback today in shares of Gilead Sciences (GILD) to concerns over the company's HIV franchise given UnitedHealth's (UNH) promotions of cheaper alternatives. UnitedHealth (UNH) is offering a rewards plan to patients starting with HIV medications to help promote the use of lower priced drugs, Jefferies analyst Michael Yee pointed out earlier today in a research note. Raffat, however, does not see risk to Gilead's sales from the promotions. UnitedHealth's is proposing a switch to two separate tablets, which is not in the HIV guidelines today, says the analyst. He keeps an Outperform rating on Gilead shares, which are down 6% to $68.00 in afternoon trading.
10/31/18
MZHO
10/31/18
NO CHANGE
Target $94
MZHO
Buy
Mizuho says concerns over UnitedHealth program impact on Gilead seem unwarranted
Mizuho analyst Salim Syed blames UnitedHealth's (UNH) introduction of a new a program, called "My ScriptRewards," that will try to convince plan participants to take a cheaper HIV regimen in return for $500 in debit cards for the weakness in shares of Gilead (GILD). However, the analyst views the worries as unwarranted, noting that Cimduo is the "common thread" between all of the regimens that UnitedHealth's program calls out and it is an inferior drug to Gilead's Biktarvy. Biktarvy is the backbone of the number one recommended regimen according to HHS treatment guidelines, noted Syed, who keeps a Buy rating and $94 price target on Gilead shares.
11/19/18
CANT
11/19/18
NO CHANGE
Target $68
CANT
Overweight
Tesaro could be worth $89-$97 per share in buyout, says Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young believes Tesaro (TSRO) could be valued at $89-$97 per share in a takeout scenario. The stock closed Friday up 31%, or $8.37, to $34.96 after Bloomberg reported that the company was exploring a sale after receiving some interest. The press article could be a way of garnering interest for the company beyond potentially initial interest, Young tells investors in a research note. In the past, she thinks Tesaro has been a potential takeout interest from biopharmaceutical companies. Companies like Amgen (AMGN), Gilead (GILD), and Celgene (CELG) have cancer platforms that could add a PARP inhibitor and benefit from Tesaro's various immuno-oncology pipeline assets, Young writes. She reiterates an Overweight rating on Tesaro with a $68 price target.
12/02/18
PIPR
12/02/18
NO CHANGE
Target $12
PIPR
Overweight
Alpine Immune Sciences' ALPN-101 active in GvHD, CTA by YE18, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff notes that Alpine (ALPN) presented two posters at ASH on proprietary variable Immunoglobulin Domain technology. In vivo data at ASH showed single doses enhanced survival in GvHD models compared to Bristol Myer's (BMY) Nujolix, he notes, adding that a CTA for ALPN-101 by YE18 should enable healthy volunteer data and lead to a Phase II GvHD start next year. The analyst also points out that Alpine presented novel Transmembrane ImmuneModulatory Proteins that can be engineered into T cells to enhance response in immunosuppressive environments. Importantly these strategies differ from TIP technology partnered to Kite (GILD) and offer further partnering opportunity, Tenthoff contends. He reiterates an Overweight rating and $12 price target on Alpine's shares.
RHHBY Roche
$0.00

(0.00%)

11/13/18
LEER
11/13/18
INITIATION
Target $18
LEER
Outperform
AC Immune initiated with an Outperform at Leerink
Leerink analyst Marc Goodman started AC Immune with an Outperform and $18 price target as he initiates Neuroscience space with a Positive View. The analyst believes the Neuroscience sector is experiencing a "renaissance" as multiple new agents and mechanisms are coming up the pipeline across major therapeutic areas, the number of clinical studies is growing nicely, and the FDA is friendly to innovation in this space, companies are getting smarter about speed-to-market strategies and selecting niche sub-populations to focus on for initial product approvals, payer pushback on usage is much lower than in other categories, and physicians are enthusiastic about new agents. Regarding AC Immune, Goodman notes that it has a diversified pipeline of drug candidates and diagnostics for Alzheimer's disease led by a late stage antibody with crenezumab, and has strong partners with Roche (RHHBY) for crenezumab, Johnson & Johnson (JNJ) for Anti-Tau vaccine, Biogen (BIIB) for alphasynuclein-PET tracer diagnostic, and Piramal for TauPET tracer diagnostic.
11/19/18
WELS
11/19/18
NO CHANGE
WELS
Pfizer price hikes may bring industry scrutiny, says Wells Fargo
Pfizer's (PFE) plans to raise prices on a host of medicines may put the drug industry "further in the crosshairs of an administration and Congress that is set on lowering drug prices," Wells Fargo analyst David Maris tells investors in a research note. The analyst points out that Pfizer earlier this year was criticized by the Trump administration for drug price increases, and as a result, it rolled the price increases back. However, Pfizer's new price increases "are not egregious" and its advance warning may be an attempt to see if minor price increases will also bring the administration's rebuke, says Maris. Nonetheless, given how public the administration's previous rebuke was, the analyst thinks Pfizer's confirmation Friday could "enflame the debate around drug pricing, especially since it comes less than two weeks following an election that resulted in Democrat control of the House with many having run on a drug-price-controls/Medicare-for-All platforms." Other large drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).
11/19/18
GSCO
11/19/18
DOWNGRADE
GSCO
Buy
Roche downgraded to Buy from Conviction Buy at Goldman Sachs
Goldman Sachs analyst Katherine Alexakis removed Roche from her firm's Conviction List but keeps a Buy rating on the shares. A number of "sentiment overhangs" in the near-term, namely the launch of U.S. biosimilars, combined with a lack of tangible catalysts could limit share upside, says the analyst.
11/26/18
SBSH
11/26/18
NO CHANGE
SBSH
Citi opens positive catalyst watch on Roche
Citi analyst Andrew Baum opened a positive catalyst watch on Roche (RHHBY) shares saying he expects CD20-TCB data at the American Society of Hematology meeting to report overall response rate and complete response "materially higher" than the 38% and 24% reported in the abstract as doses are escalated from 1800 microgams up to 60 milligrams. Further, unlike the Genentech and Regeneron (REGN) antibodies, Roche has seen no neurotoxicity with their CD20-TCB, says Baum. The analyst anticipates that Roche's CD20-TCB will look superior to Genentech's CD20/CD3 and Regeneron's REGN1979 on safety. He keeps a Neutral rating on Roche.

TODAY'S FREE FLY STORIES

JNPR

Juniper

$27.99

0.16 (0.57%)

21:01
01/23/19
01/23
21:01
01/23/19
21:01
Hot Stocks
Juniper selected by BroadBand Tower to build Japan 5G data center »

Juniper Networks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

  • 07

    Feb

PTC

PTC

$84.73

-1.14 (-1.33%)

20:28
01/23/19
01/23
20:28
01/23/19
20:28
Recommendations
PTC analyst commentary  »

PTC price target lowered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

UNP

Union Pacific

$154.20

-0.8 (-0.52%)

, BMY

Bristol-Myers

$49.92

0.21 (0.42%)

20:25
01/23/19
01/23
20:25
01/23/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

UNP

Union Pacific

$154.20

-0.8 (-0.52%)

BMY

Bristol-Myers

$49.92

0.21 (0.42%)

LUV

Southwest

$50.97

0.425 (0.84%)

MKC

McCormick

$139.03

0.31 (0.22%)

FCX

Freeport McMoRan

$12.30

-0.08 (-0.65%)

GWW

Grainger

$297.12

-3.29 (-1.10%)

AAL

American Airlines

$31.57

-1.18 (-3.60%)

HBAN

Huntington Bancshares

$13.56

0.05 (0.37%)

TXT

Textron

$49.19

0.76 (1.57%)

JBLU

JetBlue

$17.23

-0.13 (-0.75%)

AEP

American Electric

$77.00

0.65 (0.85%)

TAL

TAL Education

$31.21

-0.01 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 28

    Jan

  • 07

    Feb

  • 18

    Feb

  • 28

    Feb

  • 18

    May

  • 20

    May

ADTN

Adtran

$12.25

0.49 (4.17%)

20:14
01/23/19
01/23
20:14
01/23/19
20:14
Earnings
Adtran reports Q4 adjusted EPS (12c), consensus (3c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

MSFT

Microsoft

$106.77

0.91 (0.86%)

, GOOGL

Alphabet Class A

$1,085.27

6.59 (0.61%)

20:10
01/23/19
01/23
20:10
01/23/19
20:10
Periodicals
China blocks Microsoft's Bing search engine, FT reports »

China regulators have…

MSFT

Microsoft

$106.77

0.91 (0.86%)

GOOGL

Alphabet Class A

$1,085.27

6.59 (0.61%)

BIDU

Baidu

$163.22

2.81 (1.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 30

    Jan

  • 04

    Feb

  • 25

    Feb

  • 03

    Mar

  • 04

    Mar

  • 06

    Mar

  • 07

    Mar

EBAY

eBay

$32.62

-0.3 (-0.91%)

20:03
01/23/19
01/23
20:03
01/23/19
20:03
Recommendations
eBay analyst commentary at Baird »

eBay should consider…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

CLR

Continental Resources

$45.30

-0.27 (-0.59%)

20:00
01/23/19
01/23
20:00
01/23/19
20:00
Conference/Events
Continental Resources to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

APY

Apergy

$33.20

-0.35 (-1.04%)

19:55
01/23/19
01/23
19:55
01/23/19
19:55
Initiation
Apergy initiated at Gabelli »

Apergy initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Feb

  • 19

    Feb

AMZN

Amazon.com

$1,641.50

7.35 (0.45%)

19:15
01/23/19
01/23
19:15
01/23/19
19:15
Hot Stocks
AWS unveils Amazon WorkLink solution »

Amazon Web Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 28

    Jan

  • 31

    Jan

  • 04

    Feb

  • 20

    Feb

  • 03

    Mar

SMBK

SmartFinancial

$18.35

0.21 (1.16%)

19:08
01/23/19
01/23
19:08
01/23/19
19:08
Earnings
SmartFinancial reports Q4 operating EPS 43c, consensus 37c »

SmartFinancial Chairman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

MLRYY

Mail.Ru Group

$0.00

(0.00%)

19:05
01/23/19
01/23
19:05
01/23/19
19:05
Downgrade
Mail.Ru Group rating change at Goldman Sachs »

Mail.Ru Group downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BABA

Alibaba

$152.03

-0.1 (-0.07%)

18:58
01/23/19
01/23
18:58
01/23/19
18:58
Periodicals
Zhongnan Group to buy Alibaba-backed EasyHome for CNY38B, Bloomberg says »

Alibaba owns a 15% stake…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 03

    Mar

  • 04

    Mar

JPM

JPMorgan

$102.72

-0.23 (-0.22%)

18:55
01/23/19
01/23
18:55
01/23/19
18:55
Periodicals
JPMorgan exec says private bank expands ops in Mexico, Reuters says »

JPMorgan's private…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

SLM

Sallie Mae

$9.49

0.1 (1.07%)

, XLNX

Xilinx

$89.55

-0.89 (-0.98%)

18:53
01/23/19
01/23
18:53
01/23/19
18:53
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: SLM…

SLM

Sallie Mae

$9.49

0.1 (1.07%)

XLNX

Xilinx

$89.55

-0.89 (-0.98%)

AZPN

Aspen Technology

$89.08

0.22 (0.25%)

LRCX

Lam Research

$139.24

-0.58 (-0.41%)

URI

United Rentals

$115.98

-2.21 (-1.87%)

TER

Teradyne

$31.93

0.13 (0.41%)

VAR

Varian Medical

$126.83

1.57 (1.25%)

CP

Canadian Pacific

$195.71

0.02 (0.01%)

TXN

Texas Instruments

$95.49

-1.05 (-1.09%)

F

Ford

$8.34

-0.17 (-2.00%)

BGG

Briggs & Stratton

$13.73

-0.46 (-3.24%)

PTC

PTC

$84.73

-1.14 (-1.33%)

CTXS

Citrix

$108.64

0.4 (0.37%)

LVS

Las Vegas Sands

$57.25

0.26 (0.46%)

FFIV

F5 Networks

$159.65

2.5 (1.59%)

CCI

Crown Castle

$110.28

1.13 (1.04%)

NCNA

NuCana

$14.37

-0.38 (-2.58%)

ADXS

Advaxis

$0.32

-0.0283 (-8.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 28

    Jan

  • 28

    Jan

  • 29

    Jan

  • 29

    Jan

  • 30

    Jan

  • 11

    Feb

  • 14

    Feb

  • 25

    Feb

  • 25

    Mar

  • 26

    Mar

  • 25

    Apr

  • 28

    May

  • 24

    Jul

  • 23

    Oct

  • 25

    Jan

FB

Facebook

$144.35

-3.45 (-2.33%)

18:41
01/23/19
01/23
18:41
01/23/19
18:41
Periodicals
Advocacy groups pushing FTC to force Facebook breakup, WSJ says »

Multiple advocacy groups…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 30

    Jan

  • 25

    Feb

  • 03

    Mar

GOOG

Alphabet

$1,076.04

5.32 (0.50%)

, GOOGL

Alphabet Class A

$1,085.27

6.59 (0.61%)

18:38
01/23/19
01/23
18:38
01/23/19
18:38
Periodicals
Devs say Google's Chrome proposal threatens ad blockers, Bloomberg says »

Developers are…

GOOG

Alphabet

$1,076.04

5.32 (0.50%)

GOOGL

Alphabet Class A

$1,085.27

6.59 (0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 04

    Feb

  • 04

    Feb

  • 25

    Feb

  • 03

    Mar

FCPT

Four Corners Property Trust

$26.58

-0.09 (-0.34%)

, BLMN

Bloomin' Brands

$19.15

0.08 (0.42%)

18:36
01/23/19
01/23
18:36
01/23/19
18:36
Recommendations
Four Corners Property Trust, Bloomin' Brands analyst commentary  »

Four Corners Property…

FCPT

Four Corners Property Trust

$26.58

-0.09 (-0.34%)

BLMN

Bloomin' Brands

$19.15

0.08 (0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

BAC

Bank of America

$28.91

-0.18 (-0.62%)

18:11
01/23/19
01/23
18:11
01/23/19
18:11
Periodicals
Bank of America appoints Mike Joo as investment operating chief, Reuters says »

Head of global rates and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Feb

  • 03

    Mar

F

Ford

$8.34

-0.17 (-2.00%)

18:08
01/23/19
01/23
18:08
01/23/19
18:08
Hot Stocks
Ford says Russian alliance 'under review' »

Says won't have to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

F

Ford

$8.34

-0.17 (-2.00%)

18:04
01/23/19
01/23
18:04
01/23/19
18:04
Hot Stocks
Breaking Hot Stocks news story on Ford »

Ford says 'not…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

CHMG

Chemung Financial

$41.99

-0.11 (-0.26%)

18:04
01/23/19
01/23
18:04
01/23/19
18:04
Earnings
Chemung Financial reports Q4 EPS $1.18, consensus $1.04 »

Reports Q4 loan loss…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$8.34

-0.17 (-2.00%)

18:03
01/23/19
01/23
18:03
01/23/19
18:03
Hot Stocks
Breaking Hot Stocks news story on Ford »

Ford says 2019 will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

F

Ford

$8.34

-0.17 (-2.00%)

18:01
01/23/19
01/23
18:01
01/23/19
18:01
Hot Stocks
Ford says 2018 auto EBIT benefited from improvement of market factors »

Says auto EBIT in 2018…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

HSIC

Henry Schein

$76.92

-0.45 (-0.58%)

17:56
01/23/19
01/23
17:56
01/23/19
17:56
Hot Stocks
Henry Schein falls after saying it will not be key supplier to VCA,Pet Partners »

Shares of Henry Schein…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSIC

Henry Schein

$76.92

-0.45 (-0.58%)

17:51
01/23/19
01/23
17:51
01/23/19
17:51
Hot Stocks
Henry Schein will no longer be key supplier to VCA and Pet Partners »

Mars, Incorporated has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.